Xyphos Biosciences, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Gene Therapy, Cell Therapy
See more in Biomedtracker

Latest on Xyphos Biosciences, Inc.

Scrip

Asia Deal Watch: Ono Inks Partnerships With Switzerland’s Numab, US Biotech Shattuck

 
• By Joseph Haas and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Ono, Numab Partner On Macrophage P

Scrip

Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug

 
• By Joseph Haas and Anju Ghangurde

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Coya And Dr Reddy’s Ink Deal For C

Scrip

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

In Vivo

2023 Will Be A Year Of Partnerships And Acquisitions For Astellas

 
• By David Wild

Sentiments around the 2023 biopharma dealmaking environment may be mixed, but Mike Luther, the global head of search and evaluation business development at Astellas Pharma, Inc. , hopes the coming ye